IFP Advisors’s Sonnet BioTherapeutics SONN Stock Holding History

IFP Advisors’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19	Closed	-$45	–	3313
2023 Q3	$45	Buy	19 +18	+1,800%	+$946	﹤0.01%	3238
2023 Q2	$70	Hold	1	–	–	﹤0.01%	3368
2023 Q1	$244	Hold	1	–	–	﹤0.01%	3259
2022 Q4	$1K	Sell	1 -10	-91%	-$2.19K	﹤0.01%	4474
2022 Q3	$13K	Buy	11 +10	+1,000%	+$5.84K	﹤0.01%	3472
2022 Q2	$13K	Hold	1	–	–	﹤0.01%	3215
2022 Q1	$13K	Hold	1	–	–	﹤0.01%	3215
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	3114
2021 Q3	$1K	Hold	1	–	–	﹤0.01%	3126
2021 Q2	$3K	Hold	1	–	–	﹤0.01%	2662
2021 Q1	$4K	Buy	+1	New	+$6.32K	﹤0.01%	2496
2020 Q4	–	Hold	0	–	–	–	2658
2017 Q2	–	Hold	0	–	-$1K	–	4202
2017 Q1	–	Hold	0	–	–	–	3850
2016 Q4	–	Hold	0	–	–	–	3831
2016 Q3	–	Hold	0	–	–	–	3767
2016 Q2	–	Hold	0	–	–	–	3673
2016 Q1	–	Hold	0	–	-$2K	–	3299
2015 Q4	–	Hold	0	–	–	–	3364

Other funds holding SONN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $381M AUM 19.19% 1-Year Est. Return

IFP Advisors's SONN Position: Q4 2023 in Review

IFP Advisors sold out of Sonnet BioTherapeutics (SONN) in Q4 2023, closing a stake of 19 shares — an estimated $45 sold.

IFP Advisors first reported a position in SONN in Q1 2021 and held it in 11 quarters. The position peaked at $13K in Q3 2022. 9 funds tracked by Wall St. Rank hold SONN as of Q4 2023.

IFP Advisors reported no remaining Sonnet BioTherapeutics position as of Q4 2023 after selling out during the quarter.
IFP Advisors sold 19 Sonnet BioTherapeutics shares in Q4 2023, an estimated $45.
IFP Advisors first reported a position in Sonnet BioTherapeutics in Q1 2021 and held it in 11 quarters.
IFP Advisors's Sonnet BioTherapeutics position peaked at $13K in Q3 2022.
9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2023.

Based on IFP Advisors's 13F filing for Q4 2023, filed 9 Jan 2024.